Skip to content

Author

Sarumathy Sundararajan

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Evaluating Imeglimin as a Novel Therapeutic Action Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

INTRODUCTION/OBJECTIVE Imeglimin is the first agent of the novel glimin class that targets mitochondrial dysfunction, a key pathophysiological mechanism underlying type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis aimed to evaluate the efficacy and safety of imeglimin in patients with T2DM. ME...

S. Krishnamoorthy, Sarumathy Sundararajan · 0 citations
Open access Oct 2026

Deciphering the Multi-Target Mechanisms of Imeglimin in Type 2 Diabetes Mellitus Through Integrated Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder involving insulin resistance, impaired glucose metabolism, mitochondrial dysfunction, and chronic inflammation. Imeglimin is a novel oral antidiabetic agent that improves mitochondrial function and insulin sensitivity, although its precise molecular mechan...

S. Krishnamoorthy, Sarumathy Sundararajan · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.